Order Drugs Now

TEL: 1 866 893 0369
FAX: 1 866 402 4033

Medical News

Subscribe to Newsletter

To get info on the latest products, specials and pharmacy news, please enter your e-mail address:


January 12th, 2010
Painkiller Celebrex May Reduce Risk of Skin Cancer

People with a family history of a skin disorder may be able to reduce the risk of developing skin cancer simply by taking the painkiller and prescription drug celecoxib (Celebrex), new research is suggesting. The study is still in preliminary stages and the drug is not yet approved for this specific use, but results look promising.

The skin disorder, called Gorlin syndrome, usually causes a patient to develop hundreds or thousands of cancerous lesions (basal cell carcinomas). Researchers chose to study this particular form of skin cancer because their goal was to find an element in these high-risk patients that could be transferable to the “normal” population. This could then allow for a form of chemoprevention that could decrease the rate of skin cancers in every person.

Researchers studied patients with basal cell carcinoma who took 200mgs of Canadian prescription drug Celebrex twice a day. Dr. Ervin H. Epstein Jr., senior scientist at the Children’s Hospital of Oakland Research Institute in California reported that these patients had a significantly lower amount of lesions after two years compared to those who were taking a placebo.

However, Celebrex has been found to increase cardiovascular side effects and more research is needed in order to prove its safety.

These findings can be found in the January issue of Cancer Prevention Research. For more of the latest prescription drug and medical research news, visit www.orderonlinedrugs.com


Search for Medication or Types of Conditions



: 0
Total: $0.00

view my cart check out credit cards

Find out how much you can save now!

download order form


Medicine Shoppe Pharmacy
148 #9 31205 Maclure Road
Abbotsford BC, Canada

Ph: 1-866-893-0369
Fax: 1-800-878-7930

Licence J30
Manager: S. Maan


TEL: 1 (866) 893-0369
FAX: 1 (800) 878-7930